1-丁基-3-(3-羟基丙基)-8-(三环[3.3.1.03,7]壬-3-基)-3,7-二氢-1H-嘌呤-2,6-二酮 | 524944-72-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 1-丁基-3-(3-羟基丙基)-8-(三环[3.3.1.03,7]壬-3-基)-3,7-二氢-1H-嘌呤-2,6-二酮
• 英文名称: 1-Butyl-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-3-(3-hydroxypropyl)-1H-purine-2,6-dione
• 英文别名: 1-butyl-3-(3-hydroxypropyl)-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione
• CAS: 524944-72-7
• 化学式: C₂₁H₃₀N₄O₃
• 分子量: 386.5
• InChiKey: CIBIXJYFYPFMTN-UHFFFAOYSA-N

物化性质

• 沸点：
  646.0±61.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  89.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS
  申请人：LICHTER Jay

  公开号：US20090306225A1

  公开（公告）日：2009-12-10

  Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

  本文公开了使用免疫调节剂和耳压调节剂治疗耳部疾病的组合物和方法。在这些方法中，通过将免疫调节剂和/或耳压调节剂组合物和配方直接应用于耳媒介和/或耳内靶区，或通过灌注进入耳媒介和/或耳内结构，局部给患有耳部疾病的个体进行治疗。
• Auris Formulations for Treating Otic Diseases and Conditions
  申请人：Otonomy, Inc.

  公开号：US20160228357A1

  公开（公告）日：2016-08-11

  Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

  本文介绍了使用免疫调节剂和耳压调节剂治疗耳部疾病的组合物和方法。在这些方法中，通过直接将免疫调节剂和/或耳压调节剂组合物和配方局部应用于患有耳部疾病的个体的耳媒体和/或耳内靶区，或通过灌注到耳媒体和/或耳内结构中。
• MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS
  申请人：Otonomy, Inc.

  公开号：EP3508197A1

  公开（公告）日：2019-07-10

  Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).

  本文公开了调节含聚氧乙烯酰胺制剂凝胶温度的方法。本文还描述了持续释放药物制剂，这些制剂与人体接触后会凝胶化，可通过将这些组合物和制剂直接涂抹在目标结构上或灌注到目标结构中进行给药。
• Auris formulations for treating otic diseases and conditions
  申请人：Otonomy, Inc.

  公开号：US10272034B2

  公开（公告）日：2019-04-30

  Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

  本文公开了使用免疫调节剂和耳压调节剂治疗耳部疾病的组合物和方法。在这些方法中，通过将免疫调节剂和/或免疫调节压力调节剂组合物和制剂直接施用到耳道介质和/或耳道间质目标区域，或通过灌注到耳道介质和/或耳道间质结构中，对耳道疾病患者进行局部给药。
• Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：US10618963B2

  公开（公告）日：2020-04-14

  The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

  本说明书公开了一种药物组合物，该药物组合物包含一种活性剂，可降低个体的全身免疫抑制水平，用于治疗中枢神经系统的疾病、紊乱、病症或损伤。该药物组合物通过一个剂量方案给药，该剂量方案包括至少一个疗程，每个疗程依次包括一个治疗疗程和一个非治疗间隔疗程。